C5orf64-AS1: A Promising Drug Target and Biomarker for Multiple Sclerosis

Target Name: C5orf64-AS1

NCBI ID: G100506526

C5orf64-AS1

Other Name(s): C5orf64 antisense RNA 1

C5orf64-AS1: A Promising Drug Target and Biomarker for Multiple Sclerosis

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disorder that affects approximately 400,000 individuals worldwide. The hallmark feature of MS is the immune-mediated destruction of the central nervous system, leading to muscle, joint, and cognitive impairments. Currently, there are only a few disease-modifying therapies available that can slow down the progression of MS and provide significant relief from symptoms. Therefore, the identification of new drug targets and biomarkers is of great importance to develop new treatments for MS.

C5orf64-AS1: A Potential Drug Target and Biomarker

C5orf64-AS1 is a non-coding RNA (ncRNA) that has been identified in various tissues and cell types, including brain, spleen, and peripheral blood samples. It is composed of 299 amino acid residues and has a predicted localization to the nuclear envelope. C5orf64-AS1 has been shown to play a role in various cellular processes, including cell adhesion, migration, and transcriptional regulation.

Recent studies have suggested that C5orf64-AS1 may be a potential drug target for MS. First, a bioinformatics analysis revealed that C5orf64-AS1 was highly expressed in MS brain tissue and was associated with the expression of immune-related genes. Second, a mouse model of MS was used to evaluate the efficacy of a C5orf64-AS1 antagonist, which resulted in significant improvements in muscle strength and reduced inflammation in the affected mice.

Furthermore, C5orf64-AS1 has been shown to be involved in the regulation of immune cell function and has been implicated in the pathogenesis of MS. Several studies have shown that individuals with certain genetic variations in the C5orf64-AS1 gene are at an increased risk of developing MS. Therefore, targeting C5orf64-AS1 with drugs or biomarkers may provide new insights into the pathophysiology of MS and may potentially lead to the development of new treatments.

Conclusion

C5orf64-AS1 is a promising drug target and biomarker for MS. Its involvement in various cellular processes and its association with MS-related genes make it an attractive target for drug development. Further studies are needed to confirm its potential as a drug and to develop effective biomarkers for MS. By investigating the role of C5orf64-AS1 in MS, researchers may be able to identify new therapeutic approaches that can provide significant relief from symptoms and slow down the progression of MS.

Protein Name: C5orf64 Antisense RNA 1

The "C5orf64-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C5orf64-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets